GPRO INVESTOR ALERT: The Law Offices of Vincent Wong

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
GPRO INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving GoPro, Inc. and a Lead Plaintiff Deadline of January 17, 2017

NEW YORK, Dec. 16, 2016 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased GoPro, Inc. (NASDAQ: GPRO ) securities between September 19, 2016 and November 4, 2016.

Click here to learn about the case: http://www.wongesq.com/pslra/gopro . There is no cost or obligation to you.

According to the complaint, during the Class Period, GoPro made false and misleading statements and/or failed to disclose that: (i) GoPro’s Karma drones were prone to losing power midflight, causing them to fall out of the sky; (ii) the Company had thus significantly overstated the utility of, and likely customer demand for, the Karma drone; (iii) the foregoing issue, when publicly known, would necessitate a costly recall of the Company’s Karma drones; and (iv) as a result, GoPro’s public statements were materially false and misleading at all relevant times.

On November 3, 2016, GoPro announced it would decrease revenue guidance for 2016 from a range of $1.35 billion-$1.5 billion to a range of $1.25 billion-$1.3 billion. Then on November 8, 2016, GoPro announced a recall of approximately 2,500 Karma drones.

If you suffered a loss in GoPro you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email vw@wongesq.com , by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/gopro .

Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: vw@wongesq.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 9

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 4

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
ASTS Faces a Legal Countdown – Investors Take Note

Updated Category News Views 3

AST SpaceMobile's Legal Tangle AST SpaceMobile, Inc. (NASDAQ:ASTS) finds itself neck-deep in legal quagmire, with a class action lawsuit looming large. Investors who snapped up ASTS securities between March 4, 2025, and July 15, 2026, have until November 13, 2026, to reckon their grievances before the courts. This is no joke, folks. If you've lost dough because of shaky...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 5

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
UEG's New Advisory Board: Elevating Patient Voices

Updated Category News Views 6

Breaking Ground with Patient Representation Today's not-so-sunny forecast from Barcelona wasn't about the weather. United European Gastroenterology (UEG) rolled out its shiny new Patient Representatives Advisory Board (PRAB) during UEG Week 2026. This isn't just another committee on a never-ending list—it's a serious platform aimed at turning patient murmurs into a...

Continue Reading
Lundbeck's Board Leadership Transitions into New Era

Updated Category News Views 3

A Fresh Chapter for Lundbeck's Board Leadership Lundbeck is sparking some fresh boardroom energy, and it's not just business as usual. Dorothea Wenzel, who's been steering the ship, is stepping down come 2027—AGM in sight. Now, in swings Lars Fruergaard Jørgensen, ready to grab the wheel. Yeah, we've got some seasoned pharma muscles flexing here. The Before and After:...

Continue Reading
Faith and Resilience in China: The Legacy of the Long March

Updated Category News Views 4

History's got chapters that stick with you, and the Long March is one of those stories that shake you to your core. It all started one October evening in 1934, when more than 86,000 soldiers from the Red Army found themselves on the banks of the Yudu River. It was a scene straight out of a novel: 800-odd boats held together with coffin boards and timber beams, all set to...

Continue Reading

Top 5 Most Recently Viewed Articles

Soleno Therapeutics Celebrates FDA Approval of VYKAT XR for PWS

Updated Category News Views 420

Soleno Therapeutics Announces FDA Approval for VYKAT XR Soleno Therapeutics, Inc. (NASDAQ: SLNO), a notable biopharmaceutical company, has made a significant announcement regarding the U.S. Food and Drug Administration (FDA) approval of VYKAT XR (diazoxide choline) extended-release tablets. This new treatment targets hyperphagia in individuals aged four and older...

Continue Reading
aTyr Pharma Faces Legal Challenges: Investors Urged to Act

Updated Category News Views 173

aTyr Pharma's Legal Situation and Its Implications Recent developments surrounding aTyr Pharma, Inc. (NASDAQ: ATYR) have caught the attention of investors, particularly as the company faces significant legal challenges. The situation arose from a steep decline in share value triggered by disappointing results from a key clinical trial. This decline, marked by an...

Continue Reading
Primo Brands Boosts Share Repurchase Program by $50 Million

Updated Category News Views 145

Primo Brands Boosts Share Repurchase Program Primo Brands Corporation (NYSE: PRMB) is excited to announce a significant increase in its share repurchase program. This decision, made by the Board of Directors, involves raising the repurchase authorization by $50 million, bringing the total program authorization to an impressive $300 million. This enhancement in the share...

Continue Reading
GOTRAX Partners with RSMG Select to Inspire Youth Movement

Updated Category News Views 83

GOTRAX Teams Up with RSMG Select for Youth Development GOTRAX has embarked on an inspiring journey through its partnership with RSMG Select, aimed at nurturing not just young athletes but the community at large. The collaboration has transformed the experience for youth participating in futsal, allowing for significant growth and empowerment beyond the typical sports...

Continue Reading
Zenas BioPharma Celebrates Major Milestones in Q3 2025

Updated Category News Views 245

Zenas BioPharma Celebrates Major Milestones in Q3 2025 - Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end. - Reported highly positive 12-week primary endpoint results from Phase 2 MoonStone trial of obexelimab in Relapsing MS (RMS). - Secured development and commercialization rights for three...

Continue Reading